NCT04811404撤回4 期
A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Montgomery Asberg Rating Scale
研究概览
简要总结
This pilot study will ask whether omega three fatty acids have an antidepressant effect in bipolar depression by decreasing brain inflammation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to provide informed consent
- •Diagnosis of of bipolar I or bipolar 2 disorder and currently meets criteria for a major depressive episode
- •Depression of sufficient severity to score at least 16 on the first 17 items of the Hamilton Depression Rating Scale including the atypical depression items addendum at the time of recruitment
- •Age range 18-60
- •Females of child-bearing potential must be willing to use an acceptable method of birth control throughout the study. These include abstinence, birth control pill, male condom, IUD, depo-provera, Norplant male sterilization, female sterilization
- •Not taking more than two psychotropic medications at time of recruitment to avoid polypharmacy. Participants will not have changed the dose of the medication for at least 8 weeks before enrollment.
- •Only participants with bipolar 2 disorder diagnosis may be off psychotropic medications at time of enrollment. In that case, they must not have stopped any medications within 8 weeks of enrollment.
- •Participants can be taking diphenhydramine but no benzodiazepines or other hypnotics as needed at time of enrollment.
- •Genotyping as a medium or high TSPO binding type
排除标准
- •Diagnosis of any other major psychiatric disorders such as lifetime schizophrenia, schizoaffective disorder, current psychotic features of bipolar disorder, or recent moderate substance use disorder (within 4 months of recruitment); IV drug use. Meets DSMV criteria for a manic episode, or Young Mania Rating Scale score >12, at the time of screening.
- •Previous failed trial or intolerable side effects of ethyl EPA or any other form of omega 3 fatty acids
- •A first-degree family history of schizophrenia if the participant is less than 33 years old.
- •Significant active physical illness, including blood dyscrasias, lymphomas, hypersplenism, endocrinopathies, renal failure, chronic obstructive lung disease, autonomic neuropathies, peripheral vascular disease. Any disorders with inflammation, malignancy, autoimmune or infectious etiology. Systemic blood pressure >140 or diastolic blood pressure >
- •Hemoglobin <11 in females or <13 in males.
- •Actively suicidal, as defined by expressing ideation with a plan or intent for suicide or develops suicidal ideation that requires immediate medical or treatment intervention.
- •Pregnancy, abortion or miscarriage in the two months prior to enrollment or plans to conceive during the course of the study participation
- •Lactating Women
- •ECT within the last 6 months
- •Participants who endorse a history of prior head trauma and score 1.5 standard deviations below the mean on Trailmaking A & B test
- •Metal implants, pacemaker, metal prostheses, metal orthodontic appliances or shrapnel in the body
- •Current, past or anticipated exposure to radiation, including
- •Having been badged for radiation exposure in the workplace
- •Participation in nuclear medicine protocols in the last year* *Participants will be eligible, however, if the injected dose and dosimetry of the radiotracer are known and the cumulative annual exposure of the previous studies and this study is lower than the annual limit for research participants defined by FDA (21 CFR 361.1)
- •History of claustrophobia that would prevent the participation in neuroimaging
- •Weight >350 lbs or inability to fit into the MRI scanner**
- •** If there are doubts that the MRI scanner can accommodate the physical dimensions of the participant, the participant's circumference may be measured to determine if it is less than the MR scanner limit of 55 cm. The participant may also be brought to the MRI Center and the MRI technologist will assess whether the participant will be able to fit into the MRI scanner. Metal screening and urine pregnancy testing will be done in this circumstance before the participant enters the MRI area.
- •Current anticoagulant or anti-platelet treatment including aspirin if needed daily
- •Risks of delay to treatment of known efficacy (up to 9 weeks) are too great for the participant. Risks to consider include A) Severity of presenting symptoms B) History of symptom fluctuations or deterioration C) Psychosocial conditions that make delay to treatment unreasonable
研究组 & 干预措施
Ethyl eicosapentaenoic acid
Experimental
Ethyl eicosapentaenoic acid will be given at 1G by mouth twice per day
干预措施: Ethyl Eicosapentaenoic Acid (Drug)
结局指标
主要结局
Montgomery Asberg Rating Scale
时间窗: Six weeks
Minimum value of 0, maximum value of 60; Greater score reflects greater depression severity
次要结局
未报告次要终点
研究者
Martin Lan
Assistant Professor of Psychiatry
New York State Psychiatric Institute
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Omega-3 Fatty Acids in Bipolar DisorderBipolar DisorderNCT00010868National Center for Complementary and Integrative Health (NCCIH)
终止
早期 1 期
Open Trial Determining Antidepressant Effects of Omega-3 Supplementation During PregnancyMajor Depressive Disorder in PregnancyNCT03101527William Coryell3
已完成
2 期
A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar DepressionBipolar DepressionNCT06229977Rodrigo Machado-Vieira, MD, PhD, MSc34
已完成
不适用
Omega-3 Fatty Acids in Bipolar Patients With a Low Omega-3 Index and Reduced Heart Rate VariabilityBipolar DisordersNCT00891826Ludwig-Maximilians - University of Munich55
已完成
不适用
Do Omega-3 Fatty Acids Have an Antidepressant Effect in Patients With Signs of Peripheral Inflammation?Major Depressive DisorderNCT03143075Region Skane95